Policy & Regulation
AbCellera expands collaboration with Lilly
31 July 2024 -

Antibody discovery specialist AbCellera Biologics Inc (Nasdaq:ABCL) announced on Wednesday that it has expanded its existing collaboration with pharmaceutical company Eli Lilly and Company (NYSE:LLY) to discover therapeutic antibodies for immunology, cardiovascular disease and neuroscience.

The expanded agreement builds on a successful partnership established in 2020, which included eight programmes and an exclusive licence to AbCellera's COVID-19 antibody programme.

Lilly has the right to develop and commercialise antibodies resulting from the collaboration. AbCellera will receive upfront and research payments, as well as potential milestone payments and royalties.

Login
Username:

Password: